Clinical Trials Directory

Trials / Completed

CompletedNCT00745043

Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study

Do Beta-blockers Affect the Use of Beta-agonist Inhalers in COPD?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
11 (actual)
Sponsor
Waikato Hospital · Academic / Other
Sex
All
Age
40 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These are very common conditions and many patients have both diseases. Beta-blocker drugs are extensively used in the treatment of angina, high blood pressure and after heart attacks to decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in COPD patients as they may make the breathlessness worse, but it has now been established that they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the body and the investigators do not know if they can work together or if they would cancel each other out. The investigators also do not know which of the different types of beta-blockers now available are better for COPD patients. This study will investigate what happens to the airways of people taking both of these drugs.

Conditions

Interventions

TypeNameDescription
DRUGbronchodilator response

Timeline

Start date
2005-05-01
Primary completion
2007-08-01
Completion
2007-08-01
First posted
2008-09-01
Last updated
2024-07-29

Locations

1 site across 1 country: New Zealand

Source: ClinicalTrials.gov record NCT00745043. Inclusion in this directory is not an endorsement.